Press Releases

2021

November 22, 2021
DNAtrix Announces Oral Presentation of Positive Overall Survival Data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) Annual Meeting

September 14, 2021
DNAtrix Announces the Appointment of David Liebowitz, M.D., Ph.D., as Chief Medical Officer

June 9, 2021
DNAtrix to Present at the Raymond James Human Health Innovations Conference

March 4, 2021
DNAtrix Announces First Patient Dosed in Clinical Study of DNX-2440, an OX40 Ligand Expressing Immunotherapy, in Colorectal Cancer and Other Cancers with Liver Metastasis

February 18, 2021
DNAtrix Appoints Industry Veteran Herb Cross to its Board of Directors

February 11, 2021
DNAtrix Announces Preclinical Data Demonstrating Anti-Tumor Activity of DNX-2401 in Models of Pediatric Tumors (AT/RT and CNS-PNET) Published in Clinical Cancer Research

2020

November 20, 2020
DNAtrix Announces Positive Data from Phase 2 CAPTIVE (KEYNOTE-192) Study with DNX-2401 in Patients with Recurrent Glioblastoma Highlighted in an Oral Late-Breaking Presentation During Society for Neuro-oncology (SNO) Annual Meeting

November 9, 2020
DNAtrix Announces Multiple Data Presentations, Including Late- Breaking Phase 2 CAPTIVE (KEYNOTE-192) Data in Recurrent Glioblastoma, Planned for the Society for Neuro-oncology (SNO) Annual Meeting

January 13, 2020
DNAtrix Appoints Jeff Knapp as Chief Executive Officer and to Board of Directors

2019

November 24, 2019
DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting

November 11, 2019
DNAtrix to Present Updated Results from the Phase 2 CAPTIVE / KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting

2018

November 26, 2018
DNAtrix’s Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial

November 15, 2018
DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma

November 13, 2018
DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer

November 7, 2018
Effectiveness of DNAtrix’s DNX-2440 Oncolytic Virus Expressing OX40L in Solid Tumors to be Presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer

October 24, 2018
First Clinical Study Initiated for DNX-2440, DNAtrix's Next Generation Armed Oncolytic Virus

July 2, 2018
Treatment of Pediatric Brain Tumor, DIPG, with Oncolytic Adenovirus DNX-2401 to be Presented at the 2018 International Symposium for Pediatric Neuro-Oncology​ 

May 8, 2018
Successful Delivery of DNAtrix’s Oncolytic Virus DNX-2401 to Pediatric Brain Tumors​ 

April 12, 2018
Effectiveness of DNAtrix Oncolytic Virus DNX-2440 Armed with OX40L to be Presented at the 2018 American Association for Cancer Research Annual Meeting​ 

Read Older Press Releases >